NTCELL® continues to halt progression of Parkinson’s disease

130 weeks after treatment all four patients who took part in Living Cell Technologies Limited’s Phase I/IIa clinical study of NTCELL® for Parkinson’s disease remain well and there are no safety concerns. The primary clinical endpoint of this initial open clinical study, involving the implantation of 40 NTCELL capsules into the putamen on one side of the brain only, is safety.

In all patients NTCELL treatment continues to show improvement over baseline, as measured by the Unified Parkinson’s Disease Rating Scale (UPDRS). Efficacy is most evident in the measurement of motor function.

Read more